DermaSensor CEO Cody Simmons discusses FDA-cleared skin cancer detection device and primary care expansion strategy
Summary
DermaSensor CEO Cody Simmons describes an FDA-cleared handheld device for skin cancer detection designed for primary care offices. He outlines an eight-year development path involving miniaturization, clinical studies, and FDA review, noting the company has been commercially active for over two years with 30% quarter-over-quarter revenue growth. The company utilizes channel partners like Henry Schein and MTM for distribution while seeking Category I CPT codes to standardize reimbursement. Simmons projects a total addressable market of 140,000 primary care locations and aims to deploy 15,000 devices to generate over $100 million in recurring revenue.
Episode sections
- 0:02 – 5:51
Introduction and Company Background
Cody Simmons introduces Dermasensor, an FDA-cleared handheld device for skin cancer detection in primary care, and outlines his personal and professional background.
- 5:51 – 8:53
Product Development and Commercialization Timeline
Simmons details the eight-year development path, including miniaturization, clinical studies, and FDA review, noting two years of commercial activity with 30% quarter-over-quarter revenue growth.
- 8:53 – 16:06
Channel Partnerships and Sales Strategy
The company has secured partnerships with major distributors like Henry Schein and MTM, explaining long lead times and strategies to drive demand through SPIFs and direct sales collaboration.
- 16:06 – 22:17
Device Demonstration and Clinical Workflow
Simmons demonstrates the non-invasive scanning process, which provides a risk assessment in about two minutes, potentially avoiding unnecessary referrals and biopsies.
- 22:17 – 24:06
Reimbursement and Billing Codes
Providers currently use unlisted CPT code 96999; Dermasensor plans to submit for Category I codes to standardize reimbursement and remove adoption barriers.
- 24:06 – 28:20
Pricing Models and Adoption Drivers
The company offers device purchase with annual usage fees or rental models, with adoption driven by primary care physicians in areas with limited dermatologist access.
- 28:20 – 28:46
Device Ubiquity and Pricing Strategy
Simmons states the company aims for ubiquitous access through channel partners and direct sales, ensuring pricing parity across all purchasing channels.
- 28:46 – 29:28
Adoption via Residency Training and Demand Generation
The strategy relies on integrating DermaSensor into primary care residency programs to create organic demand from new doctors trained to use the device.
- 29:28 – 29:56
Market Size and Revenue Projections
Simmons estimates a total addressable market of 140,000 primary care locations and projects that selling 15,000 devices would generate over $100 million in recurring revenue.
- 29:56 – 30:47
Growth Trajectory and Investor Outlook
The company has several hundred signed customers and expects partners to expand to thousands of devices, acknowledging uncertainty about reaching a $100 million run rate in five years.
Claims worth verifying
Dermasensor has FDA Breakthrough Device status and De Novo classification, meaning there is no similar product by definition.
Unidentified speaker ·0:07
How to verify: Check FDA database for Dermasensor's De Novo classification number and Breakthrough Device designation letter.
Dermasensor's revenue has grown about 30% quarter over quarter for two years.
Unidentified speaker ·0:50
How to verify: Review King's Crowd investor reports or company press releases for quarterly revenue figures and growth rates.
Dermasensor has signed four national channel partners, including Henry Schein.
Unidentified speaker ·0:50
How to verify: Check Henry Schein's supplier announcements or Dermasensor's press releases regarding channel partnerships.
Dermasensor is in use by over a thousand providers.
Unidentified speaker ·0:47
How to verify: Review company press releases or King's Crowd investor updates for user count metrics.
Mako Surgical was sold to Stryker for $1.6 billion.
Unidentified speaker ·3:32
How to verify: Check Stryker's SEC filings or press releases regarding the acquisition of Mako Surgical.
Dermasensor was started in 2009 by Dr. Maurice Ferre and partners.
Unidentified speaker ·3:49
How to verify: Check SEC filings (if available via King's Crowd) or company history pages for incorporation and founding dates.
Two published studies show Dermasensor is as accurate as in-person dermatologists head-to-head.
Unidentified speaker ·17:32
How to verify: Search PubMed or medical journals for peer-reviewed studies comparing Dermasensor algorithm results to dermatologist diagnoses.
97 to 100% chance of being negative for skin cancers if the device result is 'Monitor'.
Unidentified speaker ·18:48
How to verify: Review the specific clinical study publications cited by Dermasensor for negative predictive value statistics.
CPT code 96999 is an unlisted dermatologic procedure code used for billing Dermasensor.
Unidentified speaker ·22:48
How to verify: Check the AMA CPT code set for code 96999 description and usage guidelines.
Dermasensor launched with introductory pricing of $199 a month for five patients or $399 for unlimited use.
Unidentified speaker ·24:34
How to verify: Check Dermasensor's historical press releases or website archives for launch pricing announcements.
DermaSensor aims for pricing parity regardless of where a customer buys the device (channel partners vs. direct from Derma Center).
Unidentified speaker ·28:31
How to verify: Review DermaSensor's public pricing sheets or channel partner agreements if available; compare prices across different sales channels mentioned in press releases.
DermaSensor devices are already widely deployed in several major health systems.
Unidentified speaker ·28:39
How to verify: Check DermaSensor's website for case studies or press releases listing specific health system partners; search for news articles about deployments.
Management guidelines in primary care residency programs have been using DermaSensor for years.
Unidentified speaker ·29:03
How to verify: Search for primary care residency program curricula or medical training guidelines that list DermaSensor as a standard tool; look for academic papers or training manuals.
There are 140,000 primary care locations in the relevant market.
Unidentified speaker ·29:31
How to verify: Consult industry reports from sources like the American Academy of Family Physicians (AAFP) or healthcare market research firms (e.g., IBISWorld) for the number of primary care practices.
Selling 15,000 devices would result in over $100 million in recurring revenue.
Unidentified speaker ·29:44
How to verify: Calculate the implied average revenue per device ($100M / 15,000 = ~$6,666) and compare with DermaSensor's disclosed pricing or subscription models in financial filings or investor presentations.
DermaSensor has several hundred signed customers.
Unidentified speaker ·30:01
How to verify: Review DermaSensor's investor updates, press releases, or website for customer count milestones.
DermaSensor is currently raising capital.
Unidentified speaker ·30:27
How to verify: Check King'sCrowd.com for active fundraising rounds for DermaSensor; search SEC filings or crowdfunding platform announcements.
Do your own research
- Verify DermaSensor's current FDA status and De Novo/Breakthrough Device designations via the FDA database.
- Review DermaSensor's latest SEC filings (e.g., Form D, 8-K, or 10-Q) for financial disclosures, revenue figures, and investor relations data.
- Check the CMS National Correct Coding Initiative (NCCI) edits and current CPT code listings for any updates on Category I code submissions for skin cancer detection.
- Analyze clinical study data referenced by the company regarding the 97-100% negative predictive value claim, including study design and peer-reviewed publications.
- Investigate the current reimbursement landscape for unlisted CPT code 96999 and potential payer policies affecting DermaSensor adoption.
- Research the market share and distribution agreements of major medical device distributors like Henry Schein and MTM.
- Review primary care residency program curricula to assess the extent of DermaSensor integration and training adoption.
- Compare DermaSensor's pricing and rental models against competing skin cancer detection technologies and diagnostic tools.
Full transcriptexpand
- 0:02
- Unidentified speaker: Investors ask, like, oh, you know, what's your biggest competitor?
- 0:05
- Unidentified speaker: Like, well, technically we have no competitor, right?
- 0:07
- Unidentified speaker: Like per FDA, where devo products, FTA Breakthrough status, like by definition, there is no similar product to this.
- 0:15
- Unidentified speaker: Welcome to Inside Startup Investing, the only podcast where you can invest in every guest.
- 0:21
- Unidentified speaker: On this episode, I'm talking with Cody Simmons, co-founder and CEO of Dermasensor.
- 0:26
- Unidentified speaker: Cody grew up playing tennis in Florida and had his first skin biopsy at 15.
- 0:31
- Unidentified speaker: Today he runs the company behind an FDA-cleared handheld device that lets a family doctor scan a suspicious mole in about two minutes and get a second opinion on the spot.
- 0:41
- Unidentified speaker: No referral, no months-long wait for a dermatologist.
- 0:45
- Unidentified speaker: It took eight years to build.
- 0:47
- Unidentified speaker: Now it's in use by over a thousand providers.
- 0:50
- Unidentified speaker: Revenue has grown about 30% quarter over quarter for two years, and the company just signed four national channel partners, including Henry Shine.
- 0:59
- Unidentified speaker: And for the first time, everyday investors can get in, starting at $250.
- 1:04
- Unidentified speaker: King's Crowd rates DermaSensor a 4.1 out of 5.
- 1:08
- Unidentified speaker: To see the full analyst breakdown and discover how you can invest, visit KingScrowd.com.
- 1:14
- Unidentified speaker: And now, here's my conversation with Cody.
- 1:20
- Unidentified speaker: Cody, thanks so much for being with us today.
- 1:23
- Unidentified speaker: Thanks so much for having me.
- 1:25
- Unidentified speaker: Excited to speak today.
- 1:26
- Unidentified speaker: Well, listen, let's dive right in.
- 1:29
- Unidentified speaker: Tell us about your background and how you came to found Dermosensor.
- 1:33
- Unidentified speaker: Sure.
- 1:34
- Unidentified speaker: Um I actually have uh a surprisingly relevant background, I would say, uh both personally and professionally to Dermosensor.
- 1:42
- Unidentified speaker: Um so personally, uh grew up playing tennis in Florida uh and had my first biopsy as a teenager.
- 1:50
- Unidentified speaker: I think I was around 15.
- 1:52
- Unidentified speaker: Um so I'm very molly.
- 1:54
- Unidentified speaker: I don't know if you can really tell, but I'll do a demo later.
- 1:57
- Unidentified speaker: And I I've got a I joke I was born for this job.
- 1:59
- Unidentified speaker: I've got a good demo mole right on my forearm.
- 2:02
- Unidentified speaker: Um and my mom and my aunt both had early stage melanoma.
- 2:06
- Unidentified speaker: Fortunately, it was caught early, treated, they're fine.
- 2:10
- Unidentified speaker: Uh, but it always been something that, you know, our family and just kind of personal health, we were very aware of uh skin cancer.
- 2:17
- Unidentified speaker: And so um uh, but you know, separately, professionally background in biomedical engineering and business.
- 2:25
- Unidentified speaker: And so I did my graduate research uh in a bioengineering lab at Stanford.
- 2:29
- Unidentified speaker: And after that, I was at Genentech, which is a big biopharma company.
- 2:33
- Unidentified speaker: Um, it's the world leader in oncology drugs.
- 2:36
- Unidentified speaker: I was there for four years in different uh commercial strategy and business development roles.
- 2:42
- Unidentified speaker: Um, but I knew I wanted to do startup stuff.
- 2:45
- Unidentified speaker: You know, I was at uh Brown undergrad and Stanford did kind of three different startup experiences.
- 2:50
- Unidentified speaker: And um, so I knew I wanted to do that.
- 2:51
- Unidentified speaker: So, so left pharma where I felt I kind of got an industry uh foundation, right?
- 2:57
- Unidentified speaker: I didn't want to do an MD or PhD, I just did a MS.
- 3:00
- Unidentified speaker: And so it's like, okay, I'll kind of earn my stripes there.
- 3:04
- Unidentified speaker: Um, so did that for four years and then joined a very similar screen and monitoring startup called Digicite, which had blindness disease uh screening tools uh for use by frontline providers, similar to what we're doing, and also uh by patients at home.
- 3:20
- Unidentified speaker: Uh and so I was head of business development there and then was introduced to Dr.
- 3:24
- Unidentified speaker: Maurice Ferre, who's a very successful uh physician, turned entrepreneur, uh, sold his first company to GE.
- 3:32
- Unidentified speaker: A second company went public and sold to Stryker for $1.6 billion as a surgical robotics company called Mako Surgical.
- 3:39
- Unidentified speaker: Uh and so a lot of his longtime business partners, um, you know, they had uh started some companies together, invested in a lot of early stage companies together.
- 3:49
- Unidentified speaker: So we were uh Dermosensor is one of the companies that they started together uh in 2009.
- 3:55
- Unidentified speaker: There wasn't any full-time employees or anything like that.
- 3:57
- Unidentified speaker: It was almost like a privately um privately funded like NIH grant stage company, you can almost think of.
- 4:04
- Unidentified speaker: And so that device in the background is the first uh generation device that was developed with input from Boston University, who's our key academic collaborator early on.
- 4:16
- Unidentified speaker: And so you can almost see the different device generations here, uh kind of as we sort of had different concepts and uh Time magazine best invention were in that list when uh after we got FDA clearance.
- 4:27
- Unidentified speaker: So you can see it kind of went through the different generations down to what it is now.
- 4:31
- Unidentified speaker: Um so that's a bit of background on me and on the company.
- 4:36
- Unidentified speaker: And so yeah, I was introduced to them in 2016, and as Maurice put it uh to me, he said, We're looking for an in uh we're looking for someone to help turn our research project into a company.
- 4:48
- Unidentified speaker: And so for me, it was a very exciting, you know, I was 27 at the time and had had obviously had some relevant uh experience, had a uh, you know, personal uh interest in not just oncology, but but skin cancer specifically.
- 5:03
- Unidentified speaker: Um and and I'm from Florida.
- 5:05
- Unidentified speaker: I grew up in North Florida and my parents both grew up in South Florida, so I had some failing around.
- 5:10
- Unidentified speaker: And so I was like, okay, I'll I'll leave Silicon Valley and and move back to Florida and and join them and and uh as a first full-time employee and you know, CEO and co-founder, yeah.
- 5:21
- Unidentified speaker: You've been at it for a while, and and you said something that I think is interesting.
- 5:24
- Unidentified speaker: We hear this you know all the time, or maybe we don't hear it enough.
- 5:27
- Unidentified speaker: There's a lot of folks who kind of have these science projects and they don't realize how to turn it into a business, or they don't have the right people in place to turn it into a business.
- 5:37
- Unidentified speaker: Um so I always think it's it's a really positive sign when an organization recognizes, hey, this is a bit of a science project right now, and how are we going to take it to market and commercialize and build into a real business?
- 5:48
- Unidentified speaker: It's been a decade since 2016.
- 5:51
- Unidentified speaker: Tell me about the path from 2016 and now and where are you in terms of commercializing the dermosensor business?
- 6:00
- Unidentified speaker: Sure.
- 6:00
- Unidentified speaker: Yeah, no, it's funny you said that about the the science project.
- 6:03
- Unidentified speaker: I I you know I often meet kind of uh MDs and scientists that are uh an engineer is kind of excited to start something.
- 6:10
- Unidentified speaker: And obviously, being an entrepreneur myself, I'm supportive of that.
- 6:13
- Unidentified speaker: But I just I try to make sure they understand if they're successful in the fun early stage of, you know, where you wear multiple hats, it's very intellectually satisfying, right?
- 6:23
- Unidentified speaker: You're kind of you're the only person at the company, so you're basically doing every function.
- 6:28
- Unidentified speaker: But I'm like, fast forward to where if you're successful, then your life looks like my life.
- 6:32
- Unidentified speaker: Let's talk about that, right?
- 6:33
- Unidentified speaker: Board meetings, investors, we have five law firms, you know, contract review, hiring, firing.
- 6:38
- Unidentified speaker: And they're like, oh, well, that doesn't.
- 6:40
- Unidentified speaker: I was like, yeah.
- 6:40
- Unidentified speaker: So if that's not, you think kind of longer term a good fit for you, maybe you're the chief medical officer or chief science officer, and you know, or or interim CEO, right?
- 6:51
- Unidentified speaker: And you kind of understand that you're gonna want to get a more, more business uh person in that seat eventually.
- 6:58
- Unidentified speaker: Right.
- 6:58
- Unidentified speaker: Um so yeah, so for me, my was interested in the startup stuff, you know, wearing multiple hats, uh, so 2016, but did not view myself as like a product guy or clinical guy.
- 7:10
- Unidentified speaker: Those were not my areas of expertise.
- 7:13
- Unidentified speaker: And but the hope was, you know, with with Maurice and the other board members' guidance and obviously, you know, being able to hire consultants and employees and whatnot, that we figured out we ultimately did, but I did not think it would be seven years of product and clinical development.
- 7:30
- Unidentified speaker: Um so I learned a lot about study clinic running clinical studies uh from our great uh uh head of clinical affairs, Justin Frazier, and and you know, board members and whatnot, um, and consultants.
- 7:42
- Unidentified speaker: Um, but yeah, and ended up uh, you know, viewing myself more as kind of commercial business development person before joining Derby Center, but now I feel like pretty even, you know, across kind of product development, clinical development, and commercial.
- 7:57
- Unidentified speaker: We spent the first three years miniaturizing that device, you know, besides our microwave, I'll back up here for context, down to the current handheld products.
- 8:06
- Unidentified speaker: So that was about three years.
- 8:07
- Unidentified speaker: We did a couple, you know, gather more clinical data in the meantime with the big device.
- 8:12
- Unidentified speaker: Um four years running clinical studies, and then one year for the FDA review and approval process.
- 8:22
- Unidentified speaker: So that was kind of the first eight years.
- 8:24
- Unidentified speaker: So we've been commercial a little over two years now.
- 8:26
- Unidentified speaker: Uh yeah, it's been a very exciting, very exciting time.
- 8:31
- Unidentified speaker: Um, you know, we've had about 30% quarter-on-quarter growth rate now for uh about two years on average, right?
- 8:39
- Unidentified speaker: There's a little some higher quarters higher, a little higher and lower than that, but that's been the average quarter-on-quarter growth for uh about two years now.
- 8:47
- Unidentified speaker: Um in terms of contractor revenue.
- 8:50
- Unidentified speaker: Uh, and that's just with the few salespeople.
- 8:53
- Unidentified speaker: What we're very excited about now is the big new channel partnerships that we put in place.
- 8:58
- Unidentified speaker: So we announced a couple months ago um that Henry Shine that has thousands of sales reps and and hundreds, over 300, that are really focused on primary care specifically, uh, that they we are now an approved supplier for Henry Shine.
- 9:13
- Unidentified speaker: So any of those sales representatives can sell our device.
- 9:17
- Unidentified speaker: Um also MTMC uh has over 150 sales reps.
- 9:22
- Unidentified speaker: It's the largest contract sales force for medical devices in the country.
- 9:27
- Unidentified speaker: Um, so they're also a partner, and we're in the process of rolling out from a couple regions to uh work with them nationally.
- 9:34
- Unidentified speaker: Um what else do we announce?
- 9:35
- Unidentified speaker: Oh, a partnership with a um uh one of the leading uh VA resellers, uh their name's Medical Place.
- 9:43
- Unidentified speaker: Uh so they're our exclusive seller to VA locations.
- 9:46
- Unidentified speaker: They've been doing that for over 40 years.
- 9:49
- Unidentified speaker: Uh so very excited to work with them.
- 9:50
- Unidentified speaker: And then the last one we didn't aim, it's not public, but it's one of the largest health systems in the country and and therefore the world.
- 9:57
- Unidentified speaker: They employ tens of thousands of providers.
- 10:00
- Unidentified speaker: Uh, so very excited uh to work with them as well.
- 10:03
- Unidentified speaker: And we just set up the first division uh a couple weeks ago.
- 10:06
- Unidentified speaker: So ultimately that that health system partner could could generate tens of millions in revenue each year.
- 10:13
- Unidentified speaker: Help me understand all of these kind of like resellers and people that you can work with.
- 10:17
- Unidentified speaker: I I've heard about this a lot over the years from many medical uh many different medical device companies.
- 10:23
- Unidentified speaker: And I never know like, how do we think about, you know, are they selling 300 products?
- 10:28
- Unidentified speaker: And it's just kind of like if they happen to think of you when they're in the BCP's office, they can sell it.
- 10:33
- Unidentified speaker: Do they give you any forecast of you know the type of growth you can see from working with them?
- 10:39
- Unidentified speaker: Help us better understand that relationship and why they would push your product and where you kind of fit within their stack of things they're trying to sell.
- 10:47
- Unidentified speaker: Yeah, no, it's a great question.
- 10:49
- Unidentified speaker: And and I had had had some kind of uh uh peripheral exposure and experience with them while working at Ginentech and a contracting strategy role, but not, you know, directly in the trenches of selling devices before.
- 11:02
- Unidentified speaker: So it's been uh an educational process for me too.
- 11:06
- Unidentified speaker: Um, first of all, you just have to expect long time, like long lead times, right?
- 11:10
- Unidentified speaker: And that's not, you know, so Henry Schein, who who we've publicly announced, right, as a partner.
- 11:15
- Unidentified speaker: Um, I don't it's not at all a normal, so I don't think it's an insult.
- 11:19
- Unidentified speaker: This is just how kind of the healthcare industry works.
- 11:22
- Unidentified speaker: Uh there's first interest from the kind of first interest, like, okay, we're interested in moving forward with some kind of, you know, adding this as a supply supplier or maybe a pilot to actually having something uh signed and their sales reps able to sell it.
- 11:38
- Unidentified speaker: It was maybe a year and a half.
- 11:40
- Unidentified speaker: Um, and you know, one of the persons who was point on it ended up leaving, you know, stuff happens, right?
- 11:46
- Unidentified speaker: So uh uh so that was on the front end.
- 11:49
- Unidentified speaker: In terms of now being live with them, yeah, the the challenge and there is a stereotype of um, you know, it's really hard to get your product to kind of stand out with the distributors and get them to actually kind of sell it, right?
- 12:04
- Unidentified speaker: And there is a a common saying that um distributors are a bit for most products are order takers, right?
- 12:13
- Unidentified speaker: So they'd walk in, imagine walking into primary care practice, saying, Oh, hey, Dr.
- 12:17
- Unidentified speaker: X or the practice manager, you know, Ms.
- 12:19
- Unidentified speaker: Johnson, good to see you.
- 12:20
- Unidentified speaker: Um, you know, what do you what do you guys need for this month?
- 12:24
- Unidentified speaker: Right.
- 12:24
- Unidentified speaker: And so the practice manager, oh, we're running out of bandages.
- 12:27
- Unidentified speaker: We're actually we're gonna replace our waiting room furniture, you know, we need a new exam room table.
- 12:32
- Unidentified speaker: So like it's more the practice is thinking through of the catalog of thousands of products that Henry Shine sells and offers, what are the ones we want today?
- 12:43
- Unidentified speaker: Right.
- 12:44
- Unidentified speaker: Yeah.
- 12:44
- Unidentified speaker: So more order takers versus generating demand for specific products.
- 12:49
- Unidentified speaker: Right.
- 12:50
- Unidentified speaker: So that's more kind of their traditional role.
- 12:53
- Unidentified speaker: There are programs like SPIFs, right, which is basically bonuses for the sales reps.
- 12:58
- Unidentified speaker: Uh, like, hey, not just a margin, but also like the company Dermosensor, for example, could provide, you know, X dollars for each device sold.
- 13:06
- Unidentified speaker: So maybe while the sales reps there, they're kind of, oh, okay, great, yeah, we can take care of all that.
- 13:10
- Unidentified speaker: And by the way, have you heard of this new automated skin cancer scanner called Dermosensor or is Time Magazine best invention?
- 13:16
- Unidentified speaker: You know, it's in use by over a thousand providers already.
- 13:19
- Unidentified speaker: It just launched a couple years ago.
- 13:20
- Unidentified speaker: Right?
- 13:20
- Unidentified speaker: Can you kind of get them to get do that kind of one-minute pitch, right?
- 13:24
- Unidentified speaker: But how do you do that?
- 13:25
- Unidentified speaker: It's a combination of spiffs and awareness and going to their annual conferences and getting the sales reps excited.
- 13:31
- Unidentified speaker: Um, and also work, that's a big part of where MTMC comes in, which is our contract sales force partner, because they have 150 sales reps that often work hand in hand with Henry Shine.
- 13:44
- Unidentified speaker: So they sell much more limited number of products.
- 13:48
- Unidentified speaker: And so they can talk to Henry Shine reps that you know they have overlapping accounts, saying, hey, we haven't talked to, you know, Dr.
- 13:55
- Unidentified speaker: X about this new product, Dermosensor yet.
- 13:57
- Unidentified speaker: When are you heading in there next?
- 13:58
- Unidentified speaker: I'll kind of join you for that visit and I'll talk to them about Dermosensor and a couple other products.
- 14:08
- Unidentified speaker: So when you think about kind of the key growth driver for Dermosensor, is it working with all of these different groups or is that just kind of baseline what you need to do to make sure it gets into the hands of these folks?
- 14:20
- Unidentified speaker: And it's something else altogether, whether it's a mix of marketing and sales internally to then support those distributors actually getting it in folks' hands.
- 14:28
- Unidentified speaker: Yeah.
- 14:29
- Unidentified speaker: So it's it's it's a multi-pronged approach like you're suggesting.
- 14:32
- Unidentified speaker: And we just walked uh the board through this uh last week.
- 14:34
- Unidentified speaker: We had a board meeting.
- 14:36
- Unidentified speaker: That's it's like kind of, we should probably make a little kind of map or diagram.
- 14:40
- Unidentified speaker: But yeah, so we do direct sales to primary care practices like independent clinics, mostly generated through digital ads.
- 14:46
- Unidentified speaker: We do direct outreach also.
- 14:48
- Unidentified speaker: Um, also do that like conferences and whatnot with health systems.
- 14:53
- Unidentified speaker: And then the health system, so health systems, we can we can manage those, and those can ultimately be very large sales ourselves, right?
- 15:02
- Unidentified speaker: We kind of go through the one-year contracting and IT cybersecurity reviews.
- 15:07
- Unidentified speaker: Um, often right in the early days, they start with just a couple devices, but now we're seeing more and more, okay, this is already in use, you know, uh fairly broadly and quickly growing.
- 15:16
- Unidentified speaker: We'll just get a device for each of our 10 locations or each of our, you know, so we're seeing more and more of that.
- 15:21
- Unidentified speaker: Um so we have direct sales, but then the channel, some from our sales team outbound efforts, some generated through marketing.
- 15:29
- Unidentified speaker: And then we also see the distributor uh sales or the channel partner sales with Henry Shawn and MTMC generating some of those leads and kind of support them if they have questions or uh they want to talk to our reimbursement support group, things like that.
- 15:44
- Unidentified speaker: Um, so that's basically mixed private practices and health systems, and we access both directly through sales and marketing and through our channel partners.
- 15:54
- Unidentified speaker: Understood.
- 15:55
- Unidentified speaker: Hopping back to the product, let's dive in a little bit more on what Dermosensor actually does and how a PCP would utilize it in their practice.
- 16:06
- Unidentified speaker: Great.
- 16:06
- Unidentified speaker: And I'll do you one better and actually give you a real-world demo of the device.
- 16:11
- Unidentified speaker: I don't think there's many medical devices that that can actually give you a real demo like like what happened in clinical care.
- 16:18
- Unidentified speaker: And that's why I joke, I was born for this job.
- 16:20
- Unidentified speaker: I've got a good five millimeter mole right on my forearm that actually two dermatologists have wanted a biopsy uh after looking it with the dermatoscope.
- 16:28
- Unidentified speaker: But I said, A, it it hasn't changed for 15 years.
- 16:32
- Unidentified speaker: I'm highly confident it's benign.
- 16:34
- Unidentified speaker: And B, uh, because if it's malignant, it would change.
- 16:37
- Unidentified speaker: And B, I need it for my job.
- 16:39
- Unidentified speaker: So don't bob sit.
- 16:40
- Unidentified speaker: Uh so maybe be able to put my health at risk a little bit for the company, but you know, the sacrifices founders make.
- 16:47
- Unidentified speaker: Um, so I'll act like I'm the doctor and my arm is the patient.
- 16:50
- Unidentified speaker: Okay.
- 16:50
- Unidentified speaker: So, okay, Mr.
- 16:52
- Unidentified speaker: Simmons, you know, you mentioned this mole, you might be a little worried about it.
- 16:55
- Unidentified speaker: It's larger, darker, looks a little different from the ones around it.
- 16:58
- Unidentified speaker: I'm your family doctor, you know, I'm not specialized in dermatology.
- 17:02
- Unidentified speaker: Eyeball in it, I think it's pretty low risk of melanoma.
- 17:05
- Unidentified speaker: It doesn't fit like the classic melanoma criteria.
- 17:08
- Unidentified speaker: Uh, we use the ABCDs, asymmetry, border, color, diameter evolving over time.
- 17:14
- Unidentified speaker: Uh, but like I said, I'm not a dermatologist.
- 17:17
- Unidentified speaker: To be safe, we can refer you to one, you know, it does look a little different than the moles around it.
- 17:21
- Unidentified speaker: But, you know, $50 to $100 copay at a dermatologist, hours off work.
- 17:26
- Unidentified speaker: In our area, two to three month wait time.
- 17:28
- Unidentified speaker: The good news is we just got this new device that's been cleared by the FDA.
- 17:32
- Unidentified speaker: There's nine published studies, and two of them actually show head-to-head it's as accurate as in-person dermatologist.
- 17:38
- Unidentified speaker: So it'll basically provide us a non-invasive second opinion right now to see do you really need to go to dermatologist?
- 17:46
- Unidentified speaker: Um, so we'll go ahead and use a device completely non-invasive and harmless.
- 17:52
- Unidentified speaker: Like I said, it touched the screen.
- 17:53
- Unidentified speaker: First steps, just a calibration step, making sure that the device is disinfected, it's powered on, everything's working fine.
- 18:00
- Unidentified speaker: Okay, great.
- 18:02
- Unidentified speaker: So we're gonna go ahead and take five different uh recordings here.
- 18:06
- Unidentified speaker: Each one is scanning about a millimeter of tissue non-invasively.
- 18:10
- Unidentified speaker: So I'm picking up and putting different uh putting down different parts of lesion, the same way a pathologist will look at different parts of the tissue under a microscope.
- 18:18
- Unidentified speaker: But instead of sending off to pathologists, the FDA approved algorithms processing the data now, let's see what it says.
- 18:23
- Unidentified speaker: Okay, great.
- 18:24
- Unidentified speaker: Monitor.
- 18:25
- Unidentified speaker: So monitor is the lowest risk result, the negative results.
- 18:29
- Unidentified speaker: You know, there's a little booklet here that the company provides, uh, describes a bit about skin cancer, shows the different types of devices indicated for, gives examples on the ABCDEs, and here's kind of the different outputs.
- 18:42
- Unidentified speaker: So monitor is negative.
- 18:44
- Unidentified speaker: It didn't even register on the one to 10 risk scale.
- 18:48
- Unidentified speaker: Um, so I wasn't worried about it, depending on which published study you read, 97 to 100% chance of being negative uh for skin for all three skin cancers.
- 18:57
- Unidentified speaker: So no need to send you off a referral and you know to copay an hour's off work, etc.
- 19:02
- Unidentified speaker: If you want, we can take a picture of it from your phone, or I can do it from my app here in the EMR, save it, and next time uh I see you in six months, back for your uh, you know, your next appointment, we'll check it again and make sure it's not true newer changing.
- 19:15
- Unidentified speaker: Understood.
- 19:16
- Unidentified speaker: That's it.
- 19:16
- Unidentified speaker: So that, you know, two minutes just basically saved average cost of dermatology referral is around $300 uh to an insurance company, and of course the patient portion of that.
- 19:28
- Unidentified speaker: Um so when we think about kind of the uh utilization of of this product, right?
- 19:35
- Unidentified speaker: Of derma sensor, um, just to give you an example, right?
- 19:38
- Unidentified speaker: On my wife's side, I think there's been cases of melanoma, and thus my wife basically every year sets up an appointment to go get, you know, analyzed, right, by a dermatologist.
- 19:47
- Unidentified speaker: Uh a full body exam, that's the yep.
- 19:50
- Unidentified speaker: So in that case, right, kind of going preventatively, um, though I don't even think, you know, when she goes to the PCP, it's something she thinks about.
- 19:58
- Unidentified speaker: For myself, I don't really have a history of it.
- 20:00
- Unidentified speaker: Um, I don't have anything of concern.
- 20:02
- Unidentified speaker: So usually I don't even ask my PCP about it.
- 20:05
- Unidentified speaker: So is the instance that this is coming up, is it just when people have something pop up that's concerning?
- 20:11
- Unidentified speaker: They've never been to a dermatologist, or is there an even broader set of folks that might, you know, have this done to them?
- 20:17
- Unidentified speaker: Yeah.
- 20:18
- Unidentified speaker: So in our pivotal study, uh, depending on which study you read, about half to two-thirds of melanomas are initially identified by patients, family, and friends, not by medical professionals.
- 20:30
- Unidentified speaker: However, patients, family, and friends also get worried about tons of stuff that is completely benign, right?
- 20:35
- Unidentified speaker: Yep.
- 20:36
- Unidentified speaker: Um so that's kind of the challenge for the doctor is just like, okay, I get it's new, or your wife's worried about it, but just because something appears new, obviously the large, large majority of new or changing moles are fine, right?
- 20:50
- Unidentified speaker: Um, so in our pivotal study with over a thousand patients, um, it's about a two-year study with 22 study centers led by Metal Clinic, about 60% of the lesions enrolled were presented by the patient.
- 21:07
- Unidentified speaker: So the doctor agreed, okay, yeah, you're worried about it.
- 21:10
- Unidentified speaker: I'm actually a little worried about it too.
- 21:12
- Unidentified speaker: And in that study, all lesions were a biopsy.
- 21:14
- Unidentified speaker: So they're worried about enough to actually do a biopsy.
- 21:16
- Unidentified speaker: And that's how the device performance was established, right?
- 21:19
- Unidentified speaker: Comparing the device results, first biopsy results, and compared to the primary care physician results that the the uh device outperformed the physician head to head.
- 21:29
- Unidentified speaker: Right.
- 21:30
- Unidentified speaker: Um so uh so just so that's I think a helpful data point, right?
- 21:36
- Unidentified speaker: About two-thirds uh of the lesions the doctor was worried about presented initially by the patient.
- 21:44
- Unidentified speaker: Right.
- 21:44
- Unidentified speaker: But it's often not the primary reason for the physics.
- 21:48
- Unidentified speaker: They were going for an annual physical, they were there to get a steroid injection in their shoulder, they had been having pain core, right?
- 21:53
- Unidentified speaker: Kind of something else, um, and raise that as an issue also.
- 21:58
- Unidentified speaker: You know, oh, and by the way, you know, I noticed this mole, or you know, my uh son noticed this mole on my arm, right?
- 22:04
- Unidentified speaker: Something like that.
- 22:05
- Unidentified speaker: Um so it's pretty rare that patients go to primary care specifically for a skin exam.
- 22:11
- Unidentified speaker: They typically bring it up or the doctor notices something while they're there for something else.
- 22:17
- Unidentified speaker: For a PCP, um, can they bill this to healthcare?
- 22:21
- Unidentified speaker: Is there a code for it?
- 22:23
- Unidentified speaker: Um so there's general codes called EM codes, evaluation management codes, where they just document kind of what medical work did they do, how many conditions did they address, or how much time they spent with the patients, little matrix they use.
- 22:36
- Unidentified speaker: Um so obviously if they're doing a skin exam, that's considered as part of that.
- 22:39
- Unidentified speaker: There's not a code specifically for a skin exam, and there's not a code specifically for the device, but there are relevant kind of catch-all codes.
- 22:48
- Unidentified speaker: For example, CBT code 96999 is an unlisted dermatologic procedure code that um uh that our device, you know, could be billed under because it's not specific to anything.
- 23:01
- Unidentified speaker: It's okay, is it a dermatologic procedure?
- 23:04
- Unidentified speaker: Yes, it's the procedure is using advice to scan a lesion for potential cancer, right?
- 23:09
- Unidentified speaker: So that's something that uh most of our customers are using now.
- 23:12
- Unidentified speaker: And you know, it's not as easy or smooth as a standard, you know, billing for an ultrasound, for example, right, which is done tens of thousands of times every day.
- 23:21
- Unidentified speaker: Um so there's a little more work involved with the cut for the customer and then also for the insurer.
- 23:26
- Unidentified speaker: And then, you know, it's not like it's always paid for.
- 23:29
- Unidentified speaker: And so that adds a bit of friction with the customers, and so we're excited uh that we're actually planning on submitting soon for our own, they're called category one codes, which is like that's a standard, like how ultrasound and others.
- 23:40
- Unidentified speaker: Uh and that's what doctors, especially PCPs, which don't typically do as experimental procedures and work at specialist, are much more used to.
- 23:50
- Unidentified speaker: That sounds like it could be a game changer in terms of the growth because now you provide a path for them to actually get paid for it, right?
- 23:56
- Unidentified speaker: Um, and remove the friction for the customer as well.
- 23:59
- Unidentified speaker: In terms of the device, how much is the device and is there a per use fee as well, or is it just a one-time fee?
- 24:06
- Unidentified speaker: Um Yeah, so we we don't kind of publicly share device pricing.
- 24:10
- Unidentified speaker: You know, there are some slight differences uh based on, you know, kind of which how you purchase it kind of directly from us or channel partners.
- 24:18
- Unidentified speaker: But yeah, we do have um an option to kind of purchase the device, and then there's an annual usage fee.
- 24:27
- Unidentified speaker: Um, and also an option to um do like a rental model that's based on usage.
- 24:34
- Unidentified speaker: So we announced, for example, and it's not that much higher now, uh, regardless where you go, we announced at launch kind of introductory pricing of $199 a month for five patients a month.
- 24:43
- Unidentified speaker: If you think back to the cell phone like buy buying minutes, right?
- 24:48
- Unidentified speaker: Uh five patients a month or $399 a month for unlimited use.
- 24:51
- Unidentified speaker: So that was kind of the rental model we started with.
- 24:54
- Unidentified speaker: Uh we're not, you know, too far away from that now.
- 24:58
- Unidentified speaker: When I think about you know, frictions of getting doctors to adopt this, right?
- 25:02
- Unidentified speaker: It could be around, hey, there's no way for us to make money on this, um, you know, it's too cumbersome or hard to use, uh, the fee is really high to utilize it, right?
- 25:11
- Unidentified speaker: These types of things.
- 25:12
- Unidentified speaker: And that's where I was kind of getting at with this line in questioning.
- 25:15
- Unidentified speaker: So I'm curious, getting to that point, as you've been going to market, like what has been the greatest reason why someone decides to adopt this?
- 25:23
- Unidentified speaker: And what is the reason why a doctor says, hey, I'm good, I don't need this?
- 25:28
- Unidentified speaker: Yeah.
- 25:28
- Unidentified speaker: So honestly, um the how I've been summarizing what we see in terms of kind of product market fit and stickiness uh to your to your question is um what is uh the best fit for a product is doctors that want to manage skin conditions better themselves.
- 25:48
- Unidentified speaker: That could be due to professional competency reasons, that could be due, you know, to their a high-end like concierge clinic and want the newest and best technology and tools to take the provide the best care for their patients.
- 26:02
- Unidentified speaker: Um, but the most common one we see is access to dermatology.
- 26:07
- Unidentified speaker: It's just very challenging.
- 26:08
- Unidentified speaker: You know, when when um investors ask, like, oh, you know, what's your biggest competitor?
- 26:14
- Unidentified speaker: Like, well, technically we have no competitor, right?
- 26:17
- Unidentified speaker: Like per FDA, where de novo products, FTA breakthrough status, like by definition, there is no similar product to this.
- 26:24
- Unidentified speaker: Um but practically, like if you have, if you as a primary care doctor know that any skin condition you're at all worried about, you have affluent patients that are happy to take time off work and go see a specialist and can see a dermatologist whenever they want.
- 26:42
- Unidentified speaker: Do you really need to be more capable of managing dermatology conditions yourself?
- 26:46
- Unidentified speaker: It's not as meaningful, right?
- 26:48
- Unidentified speaker: Um, and so we do see that sometimes that uh uh, you know, for example, like in Miami or New York, they may want to do for their own competency, provide better service to patients and whatnot.
- 27:00
- Unidentified speaker: Um, but otherwise it's like I I remember I won't name him, but uh uh chief medical officer of the local health system here kind of passed on on doing a pilot with us.
- 27:10
- Unidentified speaker: He's like, there's dermatologists on every other block.
- 27:13
- Unidentified speaker: Like far PCVs are worried about anything, they just refer patients, and cost-wise, no one's worried about you know, paying a hundred dollar copay.
- 27:20
- Unidentified speaker: So that's you know, so rural area, uh honestly, anywhere that isn't big urban, dermatologist-filled cities has tons of great uh potential customers.
- 27:31
- Unidentified speaker: And there's some even in the big cities, right, that are concierge practices and others.
- 27:34
- Unidentified speaker: But absolutely.
- 27:35
- Unidentified speaker: No, I and I've even heard in talking with folks about derma sensor that how hard it's been for them to get you know dermatologist appointments and how many months they have to wait, and not wanting to have to wait months to know if the mole is bad or not.
- 27:46
- Unidentified speaker: I've had to make that's real.
- 27:47
- Unidentified speaker: I've had to make calls for my mom, nine-month wait time.
- 27:50
- Unidentified speaker: A board member wanted to see a department chair at a local health system.
- 27:54
- Unidentified speaker: It was in March this year, and he was told, Oh yeah, she's starting to have appointments scheduled now for January.
- 28:00
- Unidentified speaker: When do you want to meet?
- 28:01
- Unidentified speaker: And he's like, I have another cancer on my forehead, I want to treat it, but I want to see a different doctor.
- 28:06
- Unidentified speaker: Like, I have to wait nine months to get the cancer treatment.
- 28:09
- Unidentified speaker: Like, this is crazy.
- 28:11
- Unidentified speaker: Um so yeah, it's but you know, it's it's it's really challenging.
- 28:15
- Unidentified speaker: Yeah.
- 28:15
- Unidentified speaker: When you think two to three years out from now, what does success look like for you all?
- 28:20
- Unidentified speaker: Yeah, so I think success for us is, you know, really kind of access and ability to buy the device is ubiquitous, right?
- 28:28
- Unidentified speaker: Through the channel partners we're putting in place, purchasing directly from Derma Center.
- 28:31
- Unidentified speaker: And that's what we're trying to make sure kind of pricing parity is similar, you know, kind of regardless of of where a customer would buy the device.
- 28:39
- Unidentified speaker: Um, that we have many major health systems, we already have a few, right, that have deployed the device widely.
- 28:46
- Unidentified speaker: Um, and really that what you asked about earlier with the distributor partners, instead of kind of having to sell it, that doctors are aware of and asking for it, right?
- 28:57
- Unidentified speaker: Where in management guidelines within primary care residency programs have been using it for years.
- 29:03
- Unidentified speaker: So now they're out at health systems and clinics saying, well, hey, all I've learned and am used to using for suspicious lesions is derma sensors.
- 29:11
- Unidentified speaker: So like we have to get one of those, you know.
- 29:13
- Unidentified speaker: Um, I think that's what we're trying to really build the the foundation for for that kind of future.
- 29:21
- Unidentified speaker: I'll give you the last word here for investors who are interested, but they're not there yet.
- 29:25
- Unidentified speaker: They're on the line.
- 29:26
- Unidentified speaker: What do you want them to know?
- 29:28
- Unidentified speaker: Yeah, I think, you know, we just reviewed this at the board meeting.
- 29:31
- Unidentified speaker: The thing really exciting for us, we estimate it's around 15,000 devices, and there's 140,000 primary care locations, and obviously many of them are large and would use many more than one device.
- 29:44
- Unidentified speaker: So about 15,000 devices would put us at uh over 100 million in recurring revenue and we think be, you know, billion-dollar plus company.
- 29:53
- Unidentified speaker: So um doesn't seem that crazy, right?
- 29:56
- Unidentified speaker: We already have several hundred that are are signed and um you know growing quickly.
- 30:01
- Unidentified speaker: And a lot of these current customers and current partners could quickly expand to thousands themselves.
- 30:08
- Unidentified speaker: So um yeah, I I you know can't guarantee we're gonna be at a 100 million run rate in five years as planned, but there really does seem a clear path to get there and for this to really be a game-changing company that that transforms uh skin cancer detection and care.
- 30:26
- Unidentified speaker: Thanks to Cody for joining me.
- 30:27
- Unidentified speaker: DermaCensor is raising right now.
- 30:30
- Unidentified speaker: To discover how you can invest, visit King'sCrowd.com.
- 30:34
- Unidentified speaker: And if you want our analyst take on this deal before you invest, that's exactly what King's Crowd Edge is for.
- 30:40
- Unidentified speaker: Don't forget to like and subscribe to this channel and check out the library where you can hear from other founders just like Cody.
- 30:46
- Unidentified speaker: See you next time.